M B Youdim

Summary

Affiliation: Technion-Israel Institute of Technology
Country: Israel

Publications

  1. request reprint
    Youdim M, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci. 2001;939:450-8 pubmed
  2. request reprint
    Youdim M, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev. 2005;126:317-26 pubmed
    ..These compounds have been shown to have iron chelating and monoamine oxidase A and B selective brain inhibitory and neuroprotective-antiapoptotic actions. ..
  3. Youdim M, Bakhle Y. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol. 2006;147 Suppl 1:S287-96 pubmed
    ..These aspects of MAO and its inhibition and some indication of how this important area of pharmacology and therapeutics might develop in the future are summarized in this review. ..
  4. request reprint
    Youdim M, Edmondson D, Tipton K. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295-309 pubmed
    ..We evaluate these arguments in the light of what we know, and still have to learn, of the structure, function and genetics of the monoamine oxidases and the disparate actions of their inhibitors. ..
  5. Bar Am O, Amit T, Kupershmidt L, Aluf Y, Mechlovich D, Kabha H, et al. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging. Neurobiol Aging. 2015;36:1529-42 pubmed publisher
  6. Weinreb O, Badinter F, Amit T, Bar Am O, Youdim M. Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice. Neurobiol Aging. 2015;36:2628-36 pubmed publisher
  7. request reprint
    Youdim M, Maruyama W, Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc). 2005;41:369-91 pubmed
    ..Long-term studies are required to evaluate the drug's disease-modifying prospects in Parkinson's and Alzheimer's diseases. ..
  8. request reprint
    Youdim M, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004;1012:306-25 pubmed
  9. request reprint
    Youdim M. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox Res. 2008;14:45-56 pubmed
    ..In animal models of iron deficiency it is apparent that dopaminergic interaction with the opiate system and cholinergic neurotransmission may be defective. ..

More Information

Publications10

  1. Youdim M. M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism Relat Disord. 2012;18 Suppl 1:S151-4 pubmed publisher
    ..These findings indicates that brain-permeable M30 has neurorestorative activity, which may clearly be of clinical importance for the treatment of PD. ..